A Phase 3, Randomized, Open-label Study of Subcutaneous and Intravenous VELCADE in Combination With Dexamethasone in Chinese Subjects With Relapsed or Refractory Multiple Myeloma
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 09 Feb 2018
At a glance
- Drugs Bortezomib (Primary) ; Bortezomib (Primary) ; Dexamethasone
- Indications Multiple myeloma
- Focus Therapeutic Use
- Sponsors Janssen Research & Development
- 07 Feb 2018 Status changed from recruiting to active, no longer recruiting.
- 04 May 2017 Planned End Date changed from 21 Jan 2019 to 31 Dec 2018.
- 04 May 2017 Planned primary completion date changed from 21 Jan 2019 to 31 Dec 2018.